ClinResearch, ADDPLAN, and Fulcrum Pharma Combine for Biopharm Services
A group of investors including The Halifax Group and SV Life Sciences announced a series of acquisitions that are an integral part of its strategy to build a global differentiated biopharmaceutical services company.
Led by Patrick K. Donnelly, one of the investors and former CEO of PRA International, the investment group purchased all shares of ClinResearch and ADDPLAN, global leaders in adaptive trial services and software, and Fulcrum Pharma, a UK-based company that provides comprehensive drug development, regulatory and safety services.
“With these announcements, and our previous partnership with Trio Clinical Research, we can now offer clients around the world access to innovative, comprehensive and proven development capabilities,” Mr. Donnelly said. “With the constant pressures and challenges currently facing the drug industry, we need to approach drug and device development from a different and more dynamic paradigm.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
